Creative Medical Technology Holdings Inc Asset Resilience Ratio
Creative Medical Technology Holdings Inc asset resilience ratio. Creative Medical Technology Holdings Inc (CELZ) has an Asset Resilience Ratio of 1.33% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Creative Medical Technology Holdings Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Creative Medical Technology Holdings Inc (2021–2024)
Asset resilience ratio of Creative Medical Technology Holdings Inc from 2021 to 2024. This chart shows how Creative Medical Technology Holdings Inc's Asset Resilience Ratio has changed over time. Read Creative Medical Technology Holdings Inc (CELZ) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Creative Medical Technology Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CELZ current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $125.00K | 1.33% |
| Total Liquid Assets | $125.00K | 1.33% |
Asset Resilience Insights
- Limited Liquidity: Creative Medical Technology Holdings Inc maintains only 1.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Creative Medical Technology Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Creative Medical Technology Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Creative Medical Technology Holdings Inc Asset Resilience Ratio by Year (2021–2024)
Creative Medical Technology Holdings Inc asset resilience ratio by year from 2021 to 2024. The table below shows the annual Asset Resilience Ratio data for Creative Medical Technology Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $6.67 Million | -- |
| 2023-12-31 | 60.85% | $6.52 Million | $10.72 Million | +8.32pp |
| 2022-12-31 | 52.53% | $10.08 Million | $19.19 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $11.27 Million | -- |
About Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DD… Read more